T.M., W.X., B.T.M.). *These authors contributed equally to this work. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Patients with abdominal aortic aneurysms have lower concentrations of high-density lipoproteins (HDLs), leading us to investigate whether increasing plasma HDLs could influence aneurysm formation. Methods and Results-Using the angiotensin II−induced hypercholesterolemic and the CaCl 2 -induced normocholesterolemic mouse model of AAA, we investigated the hypothesis that elevation of HDLs inhibits AAA. HDLs elevated before or at the time of AAA induction reduced AAA formation in both models but had no effect on early ruptures. Analysis of protein lysates from specific aortic segments demonstrated site-specific effects of HDLs on early signal transduction and cellular attrition. We found that HDLs reduced extracellular signal related kinases 1/2 activation in the suprarenal segment, while having no effect on p38 mitogen-associated protein kinase activation in any aortic segment and inhibiting c-Jun N-terminal kinase activation in all aortic segments. In addition, HDL elevation inhibited angiotensin II−induced apoptosis while inducing autophagy in the suprarenal segment of the aorta. Using Illumina gene array profiling we investigated the ability of HDL to modulate basal suprarenal aortic gene expression.
A bdominal aortic aneurysms (AAAs) are focal dilatations of the aorta, which commonly develop in the infrarenal segment. Little is known about the mechanism of this site specificity. 1 AAAs are often asymptomatic and can go undiagnosed until rupture. Prevalence is 4% to 7% in men and 1% to 2% in women depending on age and geographical location. 2 Aortic diameter is the most significant risk factor for aneurysmal rupture. 3 After diagnosis, growth rate is regularly monitored until the diameter reaches 5 to 5.5 cm, when the risk of rupture exceeds surgical risk. There are no pharmacological therapies for aneurysm stabilization. The demonstration that plasma concentration of high-density lipoproteins (HDLs) were lower in patients with AAA 4,5 led us to investigate whether increasing the plasma concentration of HDLs would inhibit AAA development.
Mature AAAs are matrix rich, cell poor, noncompliant, vascular dilatations, often lined with a remodelled thrombus, resulting from early inflammation, proteolysis, apoptosis, and oxidative stress. 6, 7 Involvement of these complex biological events in aneurysm pathogenesis is supported by microarray analysis of human aneurysm tissues. 8 Infiltration and activation of immune cells result in modification of the proteolytic milieu, leading to elastin degradation and compensatory collagen synthesis (particularly types I and III). 9, 10 Further infiltration of immune cells exacerbates thrombus formation, inducing ischemia-mediated neovascularisation of the developing lesion. 11, 12 Loss of smooth muscle cell plasticity, combined with increased cell death, results in medial cellular attrition. In the later stages of aneurysm formation, there is excessive degradation of elastin and increased poorly crosslinked collagens leading to weakening of the vessel wall and eventual rupture. Little is known about the precise molecular mechanisms of rupture, which has been shown to be preceded by focal neovascularisation contributing to focal weakening of the arterial wall. 13 We used 2 well documented models. In model 1, infusion of angiotensin II (Ang II) in aged hypercholesterolemic mice generates suprarenal (SR) aneurysms within 28 days from the start of infusion, mimicking several processes described in generation of human lesions. Inflammatory changes in the vasculature result in infiltration of leukocytes within the first 3 days of Ang II infusion, followed by a detectable increase in the activity of matrix metalloproteinases within the first week. [14] [15] [16] Prominent intramural hematomas are formed, after early dissection, and remodelling occurs over the following 2 weeks, resulting in reformation of circumferential elastin fibers and reendothelialization at the site of dilatation. 16 In model 2, induction of infrarenal aortic aneurysms by application of CaCl 2 to the arterial adventitia results in medial destruction and remodelling leading to dilatations within 6 weeks of injury. Analysis of CaCl 2 -induced aneurysm formation in mice deficient in matrix metalloproteinases-2 and -9 demonstrated that these enzymes work in concert to generate aneurysmal lesions. 17 HDLs are a heterogeneous family of small, dense plasma lipoprotein particles varying in size, density, lipids, proteins, apolipoproteins, and function. The dynamic remodelling is mediated through interactions with receptors and enzymes on cell membranes and other plasma lipoproteins and is concomitant with functional changes. 18, 19 In addition to mediating reverse cholesterol transport, 20, 21 HDLs have been shown to have antioxidative, 22, 23 anti-inflammatory, [24] [25] [26] [27] [28] antiapoptotic, 29, 30 and antithrombotic 31 properties. The ability of HDL to inhibit oxidative stress was supported in a recent study showing both mimetic peptides of apolipoprotein AI (ApoAI) and reconstituted discoidal HDLs (rHDLs) reduced NAD(P) H activation in an experimental model of nephropathy. 32 This broad spectrum of effects provides a functional basis for their therapeutic benefit in many complex, multigenic pathologies, such as atherosclerosis and rheumatological conditions. We investigate the effect of elevation of plasma HDL concentration as a therapeutic treatment for AAA.
We show that elevation of plasma HDL concentration inhibited Ang II−induced and CaCl 2 -induced AAA. Inhibition was concomitant with site-specific reduction in activation of extracellular signal related kinases (ERK1/2) and modulation of cell death. HDLs also modified the transcriptional profile of the aneurysm prone site, with relative changes in specific sets of genes known to inhibit aneurysm formation.
Materials and Methods

Animal Models
Experiments using Ang II−induced mice were conducted at St George's, University of London, in accordance with protocols approved by the local ethics committee. AAAs were induced in 6-month-old male C57Bl6/ApoE-deficient (ApoE −/− ) mice (Charles River, United Kingdom), by a 4-week infusion of Ang II (1μg/kg per minute) (Sigma-Aldrich, Dorset, United Kingdom), according to a well-established methodology. 33 Mice numbering 94 were randomly allocated to 5 groups (Figure I in the online-only Data Supplement). All animals had access to water and normal chow (RM1/E, SDS Diets, United Kingdom) and an osmotic pump (Alzet 2004) inserted subcutaneously in the interscapulary pouch after gaseous anesthesia, at time 0. The sham operated group (SO; n=12) had pumps delivering saline and daily (SC) injections of saline, 1 week before pump insertion and 4 weeks after. The positive control group (Gp 1, n=24) had pumps delivering Ang II and received daily (SC) injections of saline 1 week before pump insertion and 4 weeks after. The pretreatment group (Gp II, n=24) had pumps delivering Ang II and received daily (SC) injections of rHDLs (10 mg/kg; ApoAI) 1 week before pump insertion and 4 weeks after. The cotreatment groups had pumps delivering Ang II and were given daily saline injections (SC) of saline 1 week before pump insertion and daily injections (SC) of rHDLs (10 mg/kg; ApoAI) (Gp III, n=24) or pooled total native (nHDLs) (Gp IV; n=10) from the time of pump insertion and 4 weeks after.
Animals dying before termination at 4 weeks had postmortem examinations. Aneurysms were defined as lesions with a diameter of the SR aorta >50% of the normal diameter. The mean diameter of the SR aorta of the SO group was 1.24 mm; an aneurysm was defined when the SR aorta exceeded 1.86 mm in diameter. Maximal aortic diameter (mm) was estimated as an average of 5 outer-to-outer wall measurements using video micrometry, made by an investigator naive to experimental conditions (Methods and Figure II in the online-only Data Supplement). Animals were lightly sedated by (SC) injections (isofluorane:oxygen:nitrous oxide), were weighed and systolic blood pressure measured, using tail-cuff apparatus according to the manufacturer's recommendation (Harvard Instruments, Kent, United Kingdom).
The CaCl 2 -induced model experiments were conducted in the University of Nebraska (W.X., T.M., B.T.B.), as previously described. 17 All experiments were in accordance with the guidelines of the University of Nebraska Medical Centre Animal Care Committee. Mice (C57Bl/6 males, n=18) were purchased from The Jackson Laboratory (Bar Harbor, ME) and randomized to 2 groups; saline control group (saline) receiving daily (SC) saline injections and rHDL group receiving daily (SC) injections of rHDL (10 mg/kg; ApoAI). Mice were pretreated for 1 week before aneurysm induction and 6 weeks after. Mice were anesthetized and underwent laparotomy at 8 to 10 weeks old. The abdominal aorta between the renal arteries and the bifurcation of the iliac arteries were isolated from retroperitoneal structures and the aorta measured in triplicate midway between the renal artery and the iliac artery bifurcation, using a video micrometer (Colorado Video, Boulder, CO). After baseline measurements, 0.25 mol/L CaCl 2 was applied to the external surface of the aorta by application of a small cotton strip soaked in the solution. After 15 minutes the aorta was rinsed with 0.9% sterile saline and closed; mice were returned to their cages after recovery and 6 weeks later underwent laparotomy and dissection. Measurements were repeated at the same aortic location, by an observer naive to experimental treatments.
Lipoprotein Preparation and Analysis
rHDLs (CSL111) were supplied by CSL-Behring as a lyophilized compound reconstituted by the addition of sterile water, according to the manufacturer's recommendations. Native HDLs were isolated as a total mixed population of particles by sequential density gradient ultracentrifugation. HDL concentration was defined by the mass of ApoAI present, and native gradient polyacrylamide gel electrophoresis was used to determine particle heterogeneity and purity (Methods in the online-only Data Supplement).
Analysis of Kinase Activation and Cell Death
Twenty-four 6-month-old male ApoE −/− animals, were randomized to 3 groups: SO that received an osmotic pump delivering saline and daily (SC) injections of saline 1 week before pump implantation and up to 7 days after; Gp I (Ang II) that had pumps implanted delivering Ang II (1μg/kg per minute) and daily SC injections of saline 1 week before implantation and up to 7 days after; and Gp II that were implanted with pumps delivering Ang II (1μg/kg per minute) and a daily SC injection of rHDL (10 mg/kg; ApoAI) 1 week before pump implantation and up to 7 days after. Animals were euthanized at day 3 postimplantation for analysis of kinase activation and at 7 days postimplantation for analysis of markers of cell death. Protein lysates were prepared from 3 aortic segments (thoracic [TA], SR, and infrarenal/iliac [IR/IA] regions). Abundance of activated kinases (phopho-ERK1/2, p38 mitogen-associated protein kinase, or phospho−c-Jun N-terminal kinase (c-JNK) and markers of cell death (Caspase 9, cleaved poly-ADP ribose polymerase, or LC3II/ LC3I), were measured using Western blotting with specific antibodies relative to abundance of β-tubulin or a fluorimetric assay (Caspase 3/7) according to manufacturer's recommendations (Sigma-Aldrich, Dorset, United Kingdom; see Methods in the online-only Data Supplement).
Analysis of Plaque Burden and Neutral Lipid
Isolated hearts were harvested without perfusion, mounted in OCT, (ThermoScientific, West Sussex, United Kingdom), and cryostat sectioned (7−10 μm). Sections were discarded until the 3-valve cusps at the junction of the aorta and heart were clearly observed. Six further sections were collected and stained with Oil-Red-O and Russell-Movat's Pentachrome (American Master Tech, CA). The extent of neutral lipid (Oil-Red-O) and atherosclerotic plaque area were calculated from digitized low-power bright-field images using the Axiomat image analysis system (Zeiss, Herts, United Kingdom) version 4.2.3.
Transcriptional Profile Analysis
Twelve 6-month-old C57Bl6/ApoE −/− male mice randomized to 2 groups, 1 receiving daily (SC) injections of saline and 1 receiving daily (SC) injections of rHDL (10 mg/kg; ApoAI). All were euthanized after 7 days and the SR aortic segment used to generate total RNA for Illumina gene array analysis using the Ref-8 mouse chip, version 2.0 (see the online-only Data Supplement for further details and results).
Statistics
Data are reported as mean±SD, and analyzed by 1-way ANOVA, followed by Tukey post hoc correction for multiple comparisons using GraphPad Prism version 4.0 (GraphPad Prism, CA), unless stated otherwise. Percentage incidence of aortic aneurysms was analyzed by Fisher exact test. A value of P<0.05 was considered significant.
Results
HDL-Mediated Inhibition of Experimental Aneurysm Is Unrelated to Atherosclerotic Load and Independent of Hypercholesterolemia
First, we explored the effect of delivery of HDLs in the Ang II−induced hypercholesterolemic mouse model ( Figure 1 ). The pretreatment group receiving rHDL 1 week before in addition to during Ang II delivery (Gp II) showed complete inhibition of the ability to generate aneurysms compared with the positive control group (Gp I; 1.41±0.15 mm versus 2.29±0.17 mm; n=24; P<0.001). The cotreatment groups given either rHDL or pooled total nHDL, daily for the duration of Ang II (Gps III and IV), showed significant reduction in aneurysmal size, compared with the positive control group (Gp I), receiving Ang II alone, (1.45±0.22 mm, versus 1.42±0.20 mm; n=24; versus 2.29±0.17 mm; P<0.001; Figure 1 ). HDL treatment, either pretreatment (Gp II) or cotreatment (Gps III and IV), showed no difference in the number of deaths because of rupture (Table 1) . When the aneurysm and rupture data were combined, cotreatment with HDL or rHDL resulted in 37.5% or 40% incidence, whereas pretreatment resulted in a further reduction to 33% incidence. HDLs administered (SC) elevated plasma concentration of HDLs ≈2-fold but had no effect on weight or systolic blood pressure between the groups ( Table 2 ). The HDL-raising regimen used in this study was unable to significantly reduce atherosclerotic plaque burden (Figure 2A and 2B) or lipid load ( Figure 2C and 2D) .
To explore the possibility that this inhibitory effect may be influenced by hypercholesterolemia, we investigated the effect of rHDL in the CaCl 2 -induced normocholesterolemic model ( Table 3 ). Animals that received rHDLs daily 1 week before aneurysm induction and during the 6 weeks of aneurysm generation showed a significant reduction in percentage and an increased aortic expansion in comparison with a control (saline) treated with saline daily (52±13 versus 28±9 %, n=9, P=0.04).
HDL-Mediated Inhibition of Aneurysm Is Concomitant With Site-Specific Differences in Signal Transduction
Because the Ang II−induced aneurysm model is associated with early inflammatory changes, we examined the effect of rHDL on activation of protein kinases known to play a fundamental role in inflammation. We analyzed the effect of rHDL elevation in protein extracts from aortic segments of animals treated for 3 days from pump implantation. On the basis that inflammatory infiltration is observed in this model within 3 to 5 days from infusion of Ang II 16 and modulation of signal transduction is likely to precede this event, we decided to analyze protein extracts after 3 days of treatment. Kinase activation resulting from the surgical stress of the pump implantation returned to baseline levels within 48 hours and by 72 hours phosphorylation was attributable to drugs delivered rather than the surgical trauma of implantation (Methods and Figure VI in the onlineonly Data Supplement). We found that rHDLs inhibited phosphorylation of ERK1/2 in extracts from the SR and IR/IA segments, but had no effect on extracts from TA ( Figure 3A) , whereas there was no significant perturbation of p38 mitogen-associated protein kinase ( Figure 3B ). When we examined the activation of JNK, we found that rHDLs tended to inhibit Ang II−induced c-JNK activation in all aortic segments, with a significant inhibition in the SR region ( Figure 3C ).
HDL-Mediated Inhibition of Aneurysm Is Concomitant With Site-Specific Differences in Cell Death
Cell death has been shown to play an important role in the development of AAA. Recently, administration of a broadspectrum caspase inhibitor was shown to significantly reduce cell death and aneurysm formation in the Ang II−induced model. 34 We explored the ability of rHDLs to influence cell death in vivo Figure 4 .
We measured relative protein concentration of markers of cell death, in each of the 3 aortic segments. Tissues were collected from animals after 7 days of infusion. Using a fluorimetric activity assay, which detects the activity of caspase 3 and 7, we found that Ang II treatment induced ≈30% elevation of caspase 3/7 in SR extracts and a more modest elevation of caspase 3/7 activity in IR/IA extracts. In both the SR and IR/ IA extracts, rHDL treatment reduced the caspase 3/7 activity to basal levels ( Figure 4A ). Using Western blotting, we observed that Ang II−induced caspase 9 cleavage from protein lysates of the SR segment of the aorta, reduced by treatment with HDL 3.36±0.97 versus 1.10±0.78; n=4; P=0.039. No significant effect was found in either the TA or the IR/IA segment ( Figure 4B ). We found that the 89-kDa-cleaved poly-ADP ribose polymerase was significantly induced in the SR region of mice treated with Ang II (0.95±0.045) and reduced to levels observed in the SO animals (SO, 0.21±0.02) by rHDL treatment (0.25±0.034), n=4; P=0.019 ( Figure 4C ). In addition, we measured the relative conversion of LC3I to LC3II, a marker of autophagy. Although Ang II did not influence the generation of LC3II, compared with amounts found in the SO biopsies of TA or IR/IA aorta, we found that Ang II significantly decreased LC3I conversion, compared with the SR segments from SO group (2.45±0.05 in Sham versus 0.5±0.005 in Ang II; P=0.0014). In the group treated with rHDLs, LC3I conversion was elevated ≈3-fold greater than the Ang II level in TA but ≈10-fold greater than the Ang II group in SR aorta ( Figure 4D ).
Elevation of Plasma Concentration of HDLs Results in Differential Expression of Genes Important in Vascular Remodelling
Transcriptional profiling of the SR aortic segment of mice after 7 daily (SC) injections of rHDL (10 mg/kg; ApoAI) compared with the SR aortic segment of mice after 7 (SC) injections of saline shows a total of 155 genes differentially expressed, 143 induced and 12 inhibited (0<0.05 after correction of multiple measures). The raw data are registered on MIAMIExpress (HDLMmusculusmouseRef-8vs2.0, release date 2012/11/01). Quantitative real-time polymerase chain reaction validation of 6 of the top 30 induced genes have confirmed the gene array data thus far (Methods, Tables II and III in the online-only Data Supplement).
Discussion
Using 2 well-documented experimental models, we demonstrate that elevation of plasma HDLs can inhibit aneurysm formation. The inhibitory effect we achieve with rHDLs, where the sole apolipoprotein is human ApoAI, is mimicked with the use of total nHDLs, suggesting the effect may be mediated by ApoAI. We have identified 2 molecular mechanisms whereby HDLs can mediate these effects. First, we demonstrate that HDLs inhibit activation of mitogen-activated kinase, ERK1/2, and the stress activated kinase, c-JNK. Second, we demonstrate that HDLs modulate cell death via inhibition of apoptotic cell death and induction of autophagy. This differential response occurs in the SR aortae, the site specific to lesion formation in the Ang II−induced model. Most importantly, we demonstrate the ability of HDLs to mediate vascular remodelling through modulation of vascular transcriptional profile. These data provide support for the idea that pharmacological modulation of plasma HDLs could be of therapeutic benefit for the treatment of AAA and may also add to our understanding of site specificity.
Raising plasma HDLs, either before aneurysm induction or at the same time as aneurysm induction, inhibited aneurysm formation but did not influence the incidence of early dissection/rupture. These data concur with previous studies in this model, using Fenofibrate (shown to moderately elevate plasma HDLs), 35, 36 also showing reduced aneurysm formation without reductions in the incidence of early rupture. 37 The mechanism whereby elevation of HDLs is able to inhibit induction and growth of aneurysms, but not rupture, requires further investigation.
The dynamic complexity of plasma HDLs is orchestrated through interactions between lipids and proteins on cell membranes and other lipoproteins. Introduction of exogenous HDLs (either rHDLs or native total HDLs) will rapidly alter this dynamic complexity, making determination of what precise HDL subspecies is responsible for an effect a difficult task.
However, because rHDL is composed solely of human ApoAI as the only apolipoprotein, we are able to measure its kinetics of accumulation and clearance in the blood stream. We show that when rHDL is given as a single dose by (SC) injection, it can be detected in the blood stream of the animal within 4 hours, and the concentration peaks after 12 hours, consistent with previous reports. 38, 39 Using size-exclusion chromatography to analyze changes in lipoproteins over time, Chen et al 39 have shown that within 1 hour of intravenous injection of rHDL, these nascent-like discoidal pre-β particles rapidly remodel with endogenous lipoproteins into the spherical mature HDL particle.
We have explored the mechanism of this inhibition with reference to the pleiotropic functions attributed to HDLs. The most well-defined function of HDLs is in mediating removal of cholesterol from peripheral tissues via the liver, the reverse cholesterol transport pathway. The ApoE −/− mice used in this study were at least 6 months old before implantation of the osmotic pump, and although fed normal chow, the extent of atherosclerotic burden seen in these animals was extensive, with fibro-fatty lesions throughout the aortic tree. Acute elevation of plasma HDLs, achieved in these experiments, did not confer a reduction on either lipid content or plaque area in these studies, inconsistent with observations Aortic diameters were measured before incubation with CaCl 2 (pretreatment) and at euthanization (posttreatment). Measurements of aortic diameter are expressed as mean±SD. The percentage increase is represented as compared with pretreatment. The development of aneurysm was defined as an increase >50% relative to the original diameter of the aorta. *P≤0.05, Student t test, compared with pretreatment.
AAA indicates abdominal aortic aneurysms; rHDL, reconstituted discoidal high-density lipoprotein. reported after a 6-week treatment of low-density lipoprotein receptor−deficient mice with lipid-free human ApoAI. 39 However, when HDLs are elevated from birth, as in ApoE −/− mice transgenically expressing human ApoAI, a significant reduction of plaque size and lipid content was observed. 40 It may be that the short time frame of elevation of HDLs and modest increase in concentration obtained in our experiments are insufficient to effect complex changes in plaque composition. Our data support the idea that the pathological processes required for atherogenesis and aneurysm formation may have a number of divergent mechanisms. 41 We show that elevation of HDLs can inhibit Ang II−induced phosphorylation of c-JNK in vivo. Activation of c-JNK was previously identified as a key target in AAA repair in animal models and through gene expression profiling in human AAA. 42 Although Yoshimura et al showed that inhibition of c-JNK activation was concomitant with inhibition and regression of AAA in this experimental model, the investigators did not explore the site specificity of this response. Our data shows that Ang II induces activation of c-JNK in all segments of the aorta, suggesting that although activation of c-JNK may be necessary, it is not specific to aneurysm formation. We show that HDLs mediate a site-specific inhibition of ERK1/2 activation, supporting the recent data where Losartan, the selective Ang II type 1 receptor blocker, inhibited the tumor growth factor-β−mediated activation of ERK1/2, by allowing continued signaling through the Ang II type 2 receptor. 43 Cellular attrition of the aortic wall ultimately results in a weakened, noncompliant aneurysm prone to rupture.
Cellularity of the vessel wall is determined by a balance between cellular regeneration, through resident cell proliferation and stem-cell engraftment, and the processes of cell death. Cell death may also be considered a constant balance between the different forms of cell death (eg, necrosis and apoptosis and autophagy). Autophagy has been shown to be a homeostatic reparative process under normal physiological conditions. 44 Autophagy is a multistep catabolic process whereby stable proteins and organelles are sequestered in a double membrane−bound autophagosome and degraded via lysosomes. 45 However, in pathological conditions, where there is excessive induction of autophagy by environmental or intracellular stress, autophagy converts to a cell death pathway. The mechanisms that regulate the balance between autophagy and apoptosis, and hence, regulate cellular attrition, are largely unknown. Cell death through increased free cholesterol uptake has previously been described, and the increase of the autophagic process within the lipid-rich atherosclerotic plaques may be viewed as a defensive reparative process. Recent reports of autophagic gene expression in human AAA lesions 46 still raises the question as to whether this forms part of the developmental process of aneurysm formation or constitutes a reactive response to redress the loss of vascular cellularity. Our study is the first to describe a site-specific imbalance between apoptosis and autophagy in this experimental aneurysm model, which may explain the localization of lesion formation.
Oxidative stress, a major inducer of cell death, has previously been shown to play an important role in the generation of AAAs. [47] [48] [49] The antioxidative properties of HDLs are well documented and demonstrated to be largely a result of the presence of paraoxonase-1, 50,51 although ApoAI has also been shown to have antioxidant properties. 52 The fact that we observe inhibition with both total nHDLs and rHDLs supports the idea that the ameliorative effect we demonstrate may be a function of ApoAI.
Studies to determine which components of HDLs are important for maintaining the antiapoptotic properties of the lipoprotein suggest that it may be attributable to the sphingosine-1-phosphate carried on the particles, whereas others have shown it can be a function of the ApoAI. 53 Previously, we have shown that sphingosine-1-phosphate, a metabolite of ceramide induced mitogenesis, was able to suppress ceramide-mediated cell death. 54 It is also possible that rHDL particles, used in these studies, may acquire other proteins and lipid components (eg, sphingosine-1-phosphate, which may influence their function in the Ang II−induced mouse model). Further studies are required to evaluate whether these specific changes in lipoprotein complexity play a functional role in the ability of HDLs to inhibit aneurysm formation.
To mediate the profound inhibitory changes we have shown, HDLs must alter expression of a broad spectrum of genes important in aneurysm pathogenesis.
We show that of the 155 genes that are significantly modulated by increasing plasma concentration of rHDLs, 26% of the top 30 upregulated genes are involved in the synthesis, cross-linking, and degradation of extracellular matrix, known to be essential to the pathogenesis of abdominal aneurysm: Carboxypeptidase X1; Serpins A3n; tissue inhibitor of metalloproteinase-1; Prolyl Hydroxylase-β; Lysyl Oxidase; Elastin; Collagens (type 1, 5,14, and 16 α1); Osteonectin; Nidogen; Laminin B1. Twenty-five percent of the top 30 upregulated genes are involved in cell cycle progression and processing of growth factors, which also have a role in vascular remodelling: Cyclin B1; Cyclin C20; Protein Regulator of Cytokinesis; Cell Cycle Associated Protein 3. Of the top 12 downregulated genes, the membrane attack complex inhibitory factor CD59a has been previously reported to have a role in aneurysm formation 55, 56 and other genes (eg, Sortilin-1, very-low-densiy lipoprotein receptor, and Peroxisomal Bio genesis Factor) may play more of a role in modulating the changes in lipoprotein metabolism/complexity. Thus, HDL-mediated modulation of transcriptional profile may explain the ability of pretreatment with rHDL to confer additional protection against Ang II−induced aneurysm formation we have observed.
The list of potential candidate targets for aneurysm therapy is continually increasing, as differential gene expression reveals changes in expression concomitant with aneurysm formation, and investigators explore function through genetic modification. However, further investigation of the kinetics of expression, cell specificity, and functional activity of each of these genes in a variety of models is essential to fully understand their precise role in aneurysm pathobiology. For example, whereas SerpinA3n appears important in aneurysm formation, increasing circulating concentrations of Serpin A3n can inhibit early rupture of Ang II−induced aneurysms 57 but transgenic overexpression of the gene did not inhibit CaCl 2 -induced aneurysm formation. 58 Interestingly, one of the latest new candidate genes, the angiopoietin-like protein 2, a member of the large family of secreted angiopoietins, shown to accelerate CaCl 2 -induced aneurysm formation 59 has also been shown to reduce plasma concentrations of HDLs through interaction with lipoprotein lipases. 60 These studies are proof of the concept that raising plasma concentration of HDLs has potential to reduce AAA. It is a timely report, coming at a point when HDL-raising strategies are gaining momentum as a therapeutic regimen for cardiovascular diseases. Taken together, our findings support the idea that raising HDLs may provide a viable therapeutic strategy for aneurysm treatment which warrants further investigation.
